Press releases
2017
15 September, 2017
PledPharma’s CFO to leave the company in December 2017
14 September, 2017
The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group
30 August, 2017
Interim report January - June 2017
24 August, 2017
PledPharma establishes a Scientific Advisory Board for the continued clinical development of PledOx®
17 August, 2017
PledPharma appoints a Chief Medical Officer
29 June, 2017
PledPharma strengthens the management team with a Vice President Product Strategy and Development
25 April, 2017
Interim report January – March 2017
6 April, 2017
PledPharma Appoints Nicklas Westerholm as New CEO
24 February, 2017
Year end report January – December 2016
2016
20 December, 2016
Overall survival data indicates that PledOx® does not negatively interfere with the anticancer effect of chemotherapy
20 December, 2016
Overall survival data indicates that PledOx® does not negatively interfere with the anticancer effect of chemotherapy
2 December, 2016
Final result of PledPharma’s rights issue
2 December, 2016
Final result of PledPharma’s rights issue
11 November, 2016
Announcement of prospectus regarding PledPharma’s rights issue
11 November, 2016
Announcement of prospectus regarding PledPharma’s rights issue
31 October, 2016
Nominations Committee for the 2017 AGM in PledPharma AB
31 October, 2016
Nominations Committee for the 2017 AGM in PledPharma AB
20 October, 2016
PledPharma announces a guaranteed rights issue of SEK 406 million in order to take PledOx® into phase lll
20 October, 2016
PledPharma announces a guaranteed rights issue of SEK 406 million in order to take PledOx® into phase lll
20 October, 2016
Interim report January - September 2016
Calendar and upcoming reports
August 22, 2024
Interim Report Q2 2024 (7:00am CEST)
September 19, 2024
Pareto Annual Healthcare Conference
